A series
of TRPA1 antagonists is described which has as its core
structure an indazole moiety. The physical properties and <i>in vitro</i> DMPK profiles are discussed. Good <i>in vivo</i> exposure was obtained with several analogs, allowing efficacy to
be assessed in rodent models of inflammatory pain. Two compounds showed
significant activity in these models when administered either systemically
or topically. Protein chimeras were constructed to indicate compounds
from the series bound in the S5 region of the channel, and a computational
docking model was used to propose a binding mode for example compounds
Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.